Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression analysis of epidermal barrier functions associated genes in HaCaT cell treated by All-trans retinoic acid and Nicotinamide

ABSTRACT: Investigation of molecular mechanisms of impaired skin barrier by ATRA

ORGANISM(S): Homo sapiens

PROVIDER: GSE124179 | GEO | 2018/12/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression analysis of epidermal barrier functions associated genes in mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:Investigation of molecular mechanisms of impaired skin barrier by ATRA in mouse epidermis

2018-12-21 | GSE124181 | GEO

Expression analysis of epidermal barrier functions associated genes in HaCaT cell and mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-12-21 | GSE124183 | GEO

Expression analysis of epidermal barrier functions associated genes in HaCaT cell treated by All-trans retinoic acid and Nicotinamide

Project description:Expression analysis of epidermal barrier functions associated genes in HaCaT cell treated by All-trans retinoic acid and Nicotinamide

| PRJNA510952 | ENA

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Project description:The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

| 70824 | ecrin-mdr-crc

Expression analysis of epidermal barrier functions associated genes in HaCaT cell and mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:Expression analysis of epidermal barrier functions associated genes in HaCaT cell and mouse epidermis treated by All-trans retinoic acid and Nicotinamide

| PRJNA510955 | ENA

Expression analysis of epidermal barrier functions associated genes in mouse epidermis treated by All-trans retinoic acid and Nicotinamide

Project description:Expression analysis of epidermal barrier functions associated genes in mouse epidermis treated by All-trans retinoic acid and Nicotinamide

| PRJNA510954 | ENA

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:Immortalized human astrocytes were stably transfected to express IDH1 R132H. These cells were treated with 1uM ATRA

2024-04-01 | GSE252527 | GEO

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:Immortalized human astrocytes were stably transfected to express IDH1 R132H. These cells were treated with 1uM ATRA

2021-04-15 | GSE172055 | GEO

Human HL-60 Cells: all-trans retinoic acid (ATRA) vs. ATRA plus arsenic trioxide (ATO)

Project description:Transcriptional profiling of human leukemia　HL-60 cells comparing ATRA treated HL-60 cells with ATRA plus ATO. Goal was to determine the effects of ATO on ATRA induced differentiation of HL-60 cells.

2015-03-31 | GSE67420 | GEO

Human HL-60 Cells: all-trans retinoic acid (ATRA) vs. ATRA plus arsenic trioxide (ATO)

Project description:Transcriptional profiling of human leukemia?HL-60 cells comparing ATRA treated HL-60 cells with ATRA plus ATO. Goal was to determine the effects of ATO on ATRA induced differentiation of HL-60 cells. Two-condition experiment, ATRA vs. ATRA plus ATO treated HL-60 cells.

2015-03-31 | E-GEOD-67420 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data